IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Role Of Probiotics In Mitigating Gastrointestinal Disorders: Efficacy, Safety And Future Advancements

Aayu Manya Gupta[1]

[1]University Institute of Biotechnology, Chandigarh University, Mohali 140413, Punjab, India

Abstract

Gastrointestinal disorders impose a substantial global health burden, characterized by disruptions in gut function and imbalances in the gut microbiome. Probiotics have emerged as promising bioagents for managing these disorders through modulating the gut microbiota. This comprehensive review thoroughly explores the role of probiotics in mitigating gastrointestinal disorders, emphasizing efficacy, safety, and future potentials. Amidst treatment challenges posed by chronic inflammatory conditions like ulcerative colitis and Crohn's disease, probiotics offer prospective solutions by influencing immune responses, preserving intestinal barrier integrity, and impeding tumor development. Clinical investigations validate probiotics' effectiveness in treating infectious and antibiotic-associated diarrhea in adults, alongside allergic disorders in children. Furthermore, bacteriocins derived from probiotics showcase efficacy in gastrointestinal ailment management. Nevertheless, uncertainties linger in probiotics' application for managing inflammatory bowel diseases (IBD), attributed to incongruous outcomes in experimental and clinical realms. This review critically assesses the current probiotics landscape, underscoring safety considerations and advocating for optimized formulations for enhanced outcomes. A profound comprehension of probiotic mechanisms stands pivotal for steering future research and therapeutic breakthroughs. Despite challenges, probiotics hold promise in alleviating the global burden of gastrointestinal maladies, necessitating persistent research to surmount obstacles and ensure their judicious, secure, and efficacious application.

Keywords: Gastrointestinal disorders, gut function, chronic inflammatory conditions, probiotics, safety considerations, optimized formulations, therapeutic breakthroughs, global burden, persistent research, application.

Introduction

Functional gastrointestinal disorders (FGIDs) encompass a range of medical conditions characterized by diverse and varying combinations of persistent or recurring gastrointestinal symptoms. Importantly, these distressing symptoms cannot be attributed to any detectable structural or biochemical abnormalities within the digestive system. The affected regions may include the pharynx, esophagus, stomach, biliary tree, small and large intestines, or anorectum.Notably, FGIDs exert a substantial impact on a considerable segment of the population, prompting a significant number of medical consultations in primary care and gastroenterology practices (Drossman et al., 1993).

The aforementioned studies primarily focus on irritable bowel syndrome (IBS), which has been extensively investigated among the functional gastrointestinal disorders (FGIDs). Individuals dealing with FGIDs, including IBS, face challenges similar to those experienced by individuals with other chronic conditions characterized by uncertain origins and ambiguous diagnostic criteria. These chronic illnesses exhibit prolonged durations, unpredictable symptom episodes, and debilitating effects, compounded by minimally effective treatments, social stigma, and feelings of isolation. The symptoms not only burden the patients but also place significant demands on their families, leading to compromised functioning and an enduring struggle for the

affected individual (Chang et al., 2006). Altered gut microbiota composition is associated with various gastrointestinal (GI) conditions, including diarrhea, inflammatory bowel diseases (IBD), and liver diseases (Parker et al., 2018). Those with IBS frequently encounter capricious symptoms of discomfort or pain and altered bowel habits, causing emotional distress due to the lack of control over these unpredictable manifestations. Furthermore, the majority of FGIDs are more prevalent in women than men. Women are more likely to report symptoms such as globus, dysphagia, IBS, bloating, constipation, chronic functional abdominal pain, sphincter of Oddi dysfunction, fecal incontinence (at home), functional anorectal pain, and pelvic floor dysfunction. Studies suggest that functional esophageal and gastroduodenal disorders, including functional chest pain, functional heartburn, dyspepsia, and functional vomiting, do not exhibit gender differences. However, the female gender has been associated with delayed gastric emptying and lower tolerance of the water-loading test in patients with functional dyspepsia (Chang et al., 2006; Corney & Stanton, 1990; Sandler, 1990; Simren et al., 2001; Strid et al., 2001; Talley et al., 1991, 1992, 1995, 1998, 2001; TEMPLE et al., n.d.).

Probiotics have recently undergone a redefinition by a panel of experts, now characterized as 'live microorganisms which, when administered in sufficient quantities, bestow health benefits upon the host.'(FAO/WHO, 2001; Sullivan & Nord, 2005) This delineation is reinforced by a mounting corpus of evidence that underscores the advantageous repercussions arising from the consumption of probiotic-enriched foods. These health advantages encompass a spectrum of domains, most notably gastrointestinal infections and distinct bowel disorders. Among the preeminent microorganisms wielded as probiotics, lactic acid-producing lactobacilli and bifidobacteria take the forefront. These bacterial cohorts are inherent constituents of the normal microflora, with myriad strains not only limited to the production of lactic acid but also engendering a gamut of valuable antimicrobial agents, including hydrogen peroxide and bacteriocins. Furthermore, probiotic agents proactively vie for adhesion sites with pathogens and purportedly exert an influence on the host's immune retort. Despite these assertions, the precise modalities by which they interact with the immune system remain enigmatic. Microorganisms utilized as probiotics but less frequently so encompass strains of Streptococcus, Escherichia coli, Bacillus, and Saccharomyces. Of special note, Streptococcus thermophilus has been harnessed in probiotic formulations to optimize lactose digestion, particularly among individuals afflicted with lactose intolerance(Alvarez-Olmos &Oberhelman, 2001; de Vrese et al., 2001; Reid et al., 2003; Sullivan & Nord, 2002b, 2002a, 2005).

Table 1: Nomenclature for sample commercial strains of probiotics

Genus	Species	Subspecies	Strain Designation	Strain Nickname
Lactobacillus	*rhamnosus*	none	GG	LGG
Bifidobacterium	*animalis*	*lactis*	DN-173 010	*Bifidus regularis*
Bifidobacterium	*longum*	*longum*	35624	Bifantis
Saccharomyces	*boulardii*	*boulardii*	CNCM I-745	*S. boulardii*

The contemplation of probiotics as potential therapeutic avenues for gastrointestinal disorders is firmly grounded in scientifically substantiated data, illuminating their multifaceted mechanisms of action and advantageous impact on gut health. A substantial reservoir of research bolsters the rationale for harnessing probiotics in the context of gastrointestinal disorders. Principally, probiotics have showcased their ability to finely modulate the balance of the gut microbiota, fostering the proliferation of beneficial microbial species while concurrently hindering the propagation of pathogenic microorganisms. (Kailasapathy & Chin, 2000; Madlala et al., 2021; Peng et al., 2020). This equilibrium holds a pivotal role in upholding gut homeostasis and preempting dysbiosis, a phenomenon intricately linked to diverse gastrointestinal conditions, encompassing inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Scientific investigations have meticulously cataloged alterations in the composition of the gut microbiota among individuals afflicted with

these disorders, thereby lending credence to the hypothesis that probiotics might effectively contribute to the restoration of microbial equilibrium(Brown et al., 2012; Bungau et al., 2021; Nagao-Kitamoto et al., 2016; Putignani et al., 2016; Sullivan & Nord, 2002b, 2002a).This comprehensive review delves into the intricate role that probiotics play in mitigating the impact of gastrointestinal disorders, placing a specific spotlight on their effectiveness and safety. Through meticulous examination, this review assesses the present landscape of probiotics within the realm of gastrointestinal disease management, honing in on the imperative aspects of ensuring safety and refining formulations to engender more favorable outcomes.

Understanding Gastro Intestinal Diseases

The gut microbiota has been linked to triggering or exacerbating a plethora of health ailments, including, yet not limited to, inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) (Ringel, Y., Quigley, E. M., & Lin, H. C. 2012).

Inflammatory Bowel Disease

The landscape of inflammatory bowel diseases (IBDs), exemplified by conditions like Crohn's disease and ulcerative colitis, has engrossed the medical community, sparking curiosity among gastroenterologists and immunologists alike. Nestled within the realm of non-infectious bowel inflammations, these disorders have driven vigorous investigation, with contemporary methodologies unraveling profound insights into their core pathophysiological mechanisms. Idiopathic IBDs, embodied by Crohn's disease and ulcerative colitis, materialize within individuals preserving their clinical immunocompetence. The unique tapestry of symptoms and cues stemming from robust inflammation within the gastrointestinal tract orchestrates through a cytokine-driven response, definitively distinguishing them from infectious processes. Amid these distinct hallmarks, gastrointestinal manifestations including abdominal pain, diarrhea, and rectal bleeding stand alongside systemic indications such as weight loss, fever, and fatigue, as scrutinized within the exploration by Fuss et al. (2004).In contrast, the dimensions of ulcerative colitis unfurl with heightened IL-13 production, exerting a pronounced impact on the colon. This gives rise to persistent inflammation of the mucosal lining, with a pronounced focus on the rectal region and its contiguous expansion. Remarkably, a notable confluence emerges between the symptomatology characterizing ulcerative colitis and Crohn's disease, both characterized by their chronic nature and a proclivity for relapse, a theme illuminated through the insights of Fuss et al. (2004). Within this intricate interplay of factors, a tapestry of complexity unfolds, painting a more intricate portrait of the diverse landscape that defines these enigmatic inflammatory bowel diseases(Fuss et al., 2004).

The management of ulcerative colitis spans a spectrum of approaches, encompassing surgical interventions such as colon resection and medical strategies centered on established anti-inflammatory agents and immunosuppressants. In the realm of contemporary therapeutic avenues, biologic agents take the spotlight, particularly anti-TNF-α antibodies meticulously designed to target the pivotal inflammatory cytokine TNF-α. This advancement has indubitably amplified our capacity to regulate the complexities of inflammatory bowel disease (IBD). Yet, even within this treatment paradigm, challenges persist, marked by issues of waning effectiveness and the burden of associated adverse effects, as underscored in the insights of (Targan, 2006). The trajectory of this discussion converges upon a foundational premise wherein the bedrock of IBD rests upon genetically predisposed anomalies. These anomalies act as a driving force, propelling an exaggerated response from the mucosal immune system towards ordinary components of the mucosal microflora. This intricate scenario is intricately compounded by genetically driven modifications that impact the integrity of the gut epithelial barrier. This culminates in an elevated exposure of the mucosal immune system to constituents of the microflora, a perspective meticulously outlined by(Strober et al., 2007).Amidst the relentless pursuit of definitive instigating factors driving IBD, the potential therapeutic role of probiotic bacteria surfaces as an innovative avenue. Earlier investigations have cast a spotlight on the efficacy of probiotic bacteria in managing acute diarrheal illnesses. Researchers further shine a light on the protective attributes nestled within specific strains of Lactobacilli, adeptly modulating the immune response while intricately influencing the composition of the bowel flora. In tandem, recent insights gleaned from animal model studies usher in promising outcomes in the realm of chronic inflammatory bowel disease, pouchitis, and ulcerative colitis. These gains, attributed to the utilization of probiotics, lay the foundation for future research endeavors, holding the tantalizing promise of unveiling the precise role probiotic bacteria can play in steering the management of chronic inflammatory bowel disorders, an aspiration envisioned by(Schultz & Sartor, 2000).

Irritable bowel syndrome

Traditionally, irritable bowel syndrome (IBS) lacks clear structural or biochemical causation. It's a recurring functional anomaly within the gastrointestinal (GI) system, marked by abdominal discomfort and fluctuating bowel activity—constipation, diarrhea, or alternating. Accompanying sensations include bloating, incomplete evacuation, and urgency, as stated by (Hahn et al., 1999)

IBS reflects GI functional derangement, merging discomfort with defecation patterns. With high prevalence, it's linked to emotional distress, reduced quality of life, lower functionality, and higher healthcare costs(Drossman et al., 2002). Interestingly, IBS often follows acute enteric infections, particularly with diarrhea dominance or emerging functional GI disorders, indicating a potential connection. These insights enhance IBS understanding, linking symptoms and preceding factors(Ford et al., 2010)

Supporting the hypothesis of gastrointestinal infections as contributors to the pathophysiology of irritable bowel syndrome (IBS), substantial evidence stems from the research spearheaded by Walker et al. In their comprehensive investigation, they embarked on a study involving 745 individuals, randomly chosen from the population. These participants underwent a meticulously structured process that commenced with the administration of gastrointestinal symptom questionnaires. Following this, colonoscopy was performed, accompanied by the collection of terminal ileal and colonic biopsy samples. Through the application of the Rome III criteria, individuals were stratified into IBS categories, and the collected colonic biopsy specimens underwent rigorous histopathological examination.The outcomes of this meticulous study unveiled a significant finding—a subset of 17 individuals exhibited colonic spirochaetosis. Intriguingly, among these individuals, six (35%) satisfied the criteria for IBS, magnifying a notable odds ratio of 3.6 (with a 95% confidence interval of 1.27–10.11) for the co-occurrence of IBS in conjunction with spirochaetosis, relative to those without the condition. In addition to this compelling association, a distinctive pathology emerged from the colonic biopsies of those showcasing colonic spirochaetosis. This distinct pathology was characterized by heightened eosinophils and lymphoid follicles, further reinforcing the potential link between spirochaetosis and IBS(Walker et al., 2015). These findings significantly contribute to our understanding of the complex interplay between gastrointestinal infections and the intricate landscape of IBS.

Mechanisms of probiotics influencing gut environment

The gastrointestinal (GI) tract assumes a paramount role as a discerning interface demarcating the host from its environment. Within this realm, a vast assemblage of approximately 10 trillion microorganisms, spanning an array of species, takes up habitation. Collectively, these microorganisms amass to a substantial weight of 12 kg, as documented by (O'Hara & Shanahan, 2006)



Figure 1: Illustrates the intricate interplay between the indigenous microflora and probiotics within the context of the host's metabolic processes and immune functions. Additionally, this symbiotic relationship serves to thwart the establishment of opportunistic and pathogenic microorganisms, preventing their colonization. (Sullivan & Nord, 2005)

Within the intestinal milieu lies a complex and dynamic microbial ecosystem, rich in its multifaceted and perpetually shifting nature, that bestows a range of paramount functions. These functions span a gamut of activities, including intricate metabolic processes, trophic influences exerted upon the intestinal epithelium, and sophisticated interplays with the host's immune system. Moreover, the native microflora stands as a formidable bulwark, proficiently thwarting the colonization endeavors of opportunistic and pathogenic microorganisms, thus amplifying the host's protective mechanisms (EJ, 1994; Guarner &Mala gelada, 2003; Sullivan & Nord, 2005). Probiotics are implicated in augmenting the function of the gut barrier. Impaired gut barrier integrity is associated with conditions like leaky gut syndrome and celiac disease. Probiotics have been demonstrated to strengthen the gut lining by fostering the synthesis of tight junction proteins and mucin, thereby alleviating the transfer of detrimental substances across the intestinal epithelium (Albillos et al., 2020a; De Kort et al., 2011; Fasano & Shea-Donohue, 2005; König et al., 2016). Probiotics demonstrate immunomodulatory characteristics that harbor the capacity to positively impact gastrointestinal disorders. Probiotic microorganisms actively interact with the gut-associated lymphoid tissue, effectively shaping the activities of immune cells and the production of cytokines. This form of immunomodulation presents a considerable potential for mitigating the enduring inflammation that characterizes ailments like Crohn's disease and ulcerative colitis, both of which constitute integral components of the spectrum of inflammatory bowel diseases (IBD) (Albillos et al., 2020b; Ewaschuk&Dieleman, 2006; Sanz & De Palma, 2009; Thompson-Chagoyán et al., 2005). Clinical trials have furnished empirical substantiation for the application of distinct probiotic strains in the context of gastrointestinal disorders. To illustrate, strains hailing from the Bifidobacterium and Lactobacillus genera have showcased effectiveness in mitigating symptoms associated with irritable bowel syndrome (IBS), encompassing manifestations like bloating, abdominal discomfort, and perturbed bowel patterns. Furthermore, probiotics such as Saccharomyces boulardii have demonstrated proficiency in the management of antibiotic-associated diarrhea by thwarting the excessive proliferation of opportunistic pathogens (Agamennone et al., 2018; Harris &Baffy, 2017; Rodiño-Janeiro et al., 2018; Sullivan & Nord, 2005). The rationale underpinning the exploration of probiotics as potential remedies for gastrointestinal disorders is solidly grounded in an abundance of scientifically credible data. Their ability to regulate gut microbiota, impact immune responses, and bolster gut barrier integrity resonates harmoniously with the underlying pathophysiological mechanisms of diverse gastrointestinal conditions (Y. Liu et al., 2022; Yousefi et al., 2019) .

The precise mechanisms underlying the operation of probiotics remain an area that necessitates further clarification. Various potential mechanisms come under consideration in this context. These encompass the modulation of gastrointestinal (GI) immunity, which could involve altering profiles of inflammatory cytokines, downregulating cascades of proinflammatory responses, or triggering regulatory mechanisms in a strain-specific manner. Another avenue is the displacement of pathogenic bacteria, whereby probiotics might displace bacterial species responsible for gas production and bile salt deconjugation. This displacement could subsequently hinder the adherence of pathogenic bacteria, potentially contributing to a healthier microbial balance.

Furthermore, the alteration of bacterial flora through nutrient fermentation and subsequent acidification of the colon represents another potential mechanism through which probiotics might exert their effects. Additionally, probiotics could enhance the function of the epithelial barrier, which plays a crucial role in maintaining gut integrity. The induction of cellular receptors like m-opioid and cannabinoid receptors in intestinal epithelial cells is another conceivable mechanism.Beyond these considerations, the realm of probiotics extends to the prospect of modulating sensory responses within the gut. This encompasses the potential to alleviate visceral hypersensitivity, curtail spinal afferent traffic, and temper stress-induced reactions. These mechanisms intricately elucidate the multifaceted interactions that probiotics engage in within the intricate milieu of the gut environment, as underscored in the insights of (Verna &Lucak, 2010). Simultaneously, the multifarious impacts of probiotics contribute substantively to their efficacy across a spectrum of indications. This efficacy is distinctly underscored by their prowess in fortifying the intestinal barrier, exerting influence over immune responses, manifesting antibacterial properties, orchestrating motility regulation, and intricately affecting sensory perception. This intricate web of multifunctional attributes collectively accentuates the boundless potential of probiotics as therapeutic agents, spanning a diverse array of contexts and applications, as envisioned by(McFarland, 2010).

Efficacy of probiotics in Gastrointestinal Disorders

Across the United States, Europe, and worldwide, an extensive array of probiotics has gained availability, reflecting their widespread use(Guarner et al., 2008). The significance of dosage within formulations comes to the fore through a study conducted by (Whorwell et al., 2006). This investigation involved 330 individuals grappling with irritable bowel syndrome (IBS), who received three doses of encapsulated Bifidobacterium infantis (106, 108, and 1010 colony-forming units (CFU)). Strikingly, it was the 108 CFU dosage, rather than the highest dosage (1010 CFU), that proved effective in addressing the primary endpoint of alleviating pain and discomfort at the four-week mark. Intriguingly, subsequent examination disclosed that the 1010 CFU dosage congealed into a pellet impervious to dissolution. Interestingly, this issue of bioavailability did not arise when the same probiotic was introduced into a milk-based beverage, as illuminated by (Whorwell et al., 2006)

The impact of probiotics on mucosal immunity takes center stage, driven by their ability to elevate the presence of IgA-producing cells within the lamina propria and stimulate the secretion of secretory IgA into the luminal mucus layers. These orchestrated activities effectively curtail bacterial colonization of the epithelial lining, offering a protective role(O'Mahony et al., 2005). This intricate interplay between probiotics and mucosal immunity underscores their multifaceted influence within the complex tapestry of gut health.
In the broader context, it emerges that the anti-inflammatory effects of probiotics, frequently observed in in vitro and animal studies, do not always seamlessly translate into clinically beneficial outcomes. This intricacy is intertwined with the multifaceted immunomodulatory impacts exerted by probiotics, whose overall effects are often elusive to predict and distinctly specific to the ailment, health condition, and individual probiotic strain in question(De Roock et al., 2010; Sokol et al., 2008).In earlier investigations, probiotic efficacy has been evidenced in addressing an array of concerns, including inflammation-related, diarrhea-associated, and irritable bowel syndrome (IBS) symptoms. For instance, studies conducted by(Halpern et al., 1996; Hilton et al., 1997; Mimura et al., 2004)have all underscored the effectiveness of probiotics in managing symptoms linked to inflammation, diarrhea, and IBS. These instances collectively highlight the potential of probiotics as a versatile therapeutic avenue for a range of conditions.

Extensive research, including meta-analyses and clinical trials, delves into probiotics' efficacy across prevalent gastrointestinal diseases like IBS, Pouchitis, AAD (Antibiotic Associated Diarrhea), ID (Infectious Diarrhea), TD (Traveler's Diarrhea), NEC (Necrotising Enterocolitis), HPP (Helicobacter pylori infection) and CDD (Clostridium difficile disease). These investigations underscore probiotics' substantial impact on prevention and treatment. While numerous meta-analyses explore probiotics for distinct diseases, this study comprehensively assesses their relative efficacy across various ailments with unique etiologies (Hoveyda et al., 2009; Sanderson & Walker, 1993; TONG et al., 2007). Randomized controlled trials in humans deploying specific probiotic strains for treatment or prevention of above-mentioned diseases are analyzed using random effects models. The findings reveal probiotics' significant positive impact across all eight diseases, with a relative risk of 0.58 (95% CI: 0.51–0.65). Six diseases—Pouchitis, ID, IBS, HPP, CDD, AAD—show marked benefits from probiotics, except TD and NEC. Among eleven probiotic species studied, all exhibit positive effects, except L. acidophilus, L. plantarum, and B. infantis. Regardless of diseases, probiotic species, patient age, and treatment duration, positive effects persist. These results establish probiotics' broad therapeutic benefits for gastrointestinal diseases, except Traveler's Diarrhea and NEC, and specific species. Selecting probiotics for treatment or prevention should consider ailment and species, as per (Ringel et al., 2012). The effectiveness of probiotics in treating infectious diarrhea has been assessed through a meta-analysis of 63 studies (n = 8,014), with 56 studies focusing on infants and young children. The findings showed probiotics significantly reduced diarrhea duration by 24.76 hours (95% CI 15.9 – 33.6 h), lowered risk of diarrhea lasting ≥ 4 days (RR 0.41; 95% CI 0.32 – 0.53), and decreased stool frequency on day 2 (MD 0.80; 95% CI 0.45 – 1.14)(Allen et al., 2010).Similarly, in preventing antibiotic-associated diarrhea, a meta-analysis assessed probiotic efficacy, incorporating nine studies, including two in pediatric populations. The odds ratio for proactive probiotic intervention to prevent antibiotic-associated diarrhea was 0.37 (95% CI 0.26 – 0.53; $P < 0.001$). Distinctive odds ratios were noted, at 0.39 (95% CI 0.25 – 0.62; $P < 0.001$) for S. boulardii trials and 0.34 (95% CI 0.19 – 0.61; $P < 0.001$) for lactobacilli. A 2010 meta-analysis focusing on S. boulardii in antibiotic-associated diarrhea highlighted an odds ratio of 0.47 (95% CI 0.35 – 0.62) (D'souza et al., 2002). These findings emphasize probiotics' potential effectiveness, especially S. boulardii, in preventing antibiotic-associated diarrhea.

Efficacy for IBD

A systematic evaluation of the efficacy of probiotics in the realm of inflammatory bowel disease (IBD) was undertaken through a comprehensive review and meta-analysis, employing established methodologies. The search spanned MEDLINE, EMBASE, and the Cochrane Controlled Trials Register, with data scrutinized up to November 2016. Eligible randomized controlled trials (RCTs) encompassed adult participants diagnosed with either ulcerative colitis (UC) or Crohn's disease (CD). These trials entailed a comparison of probiotics against 5-aminosalicylates (5-ASAs) or a placebo. Dichotomous symptom data were synthesized, yielding relative risks (RRs) indicative of the probability of failure to attain remission in active IBD or recurrence of disease activity in quiescent IBD. All outcomes were accompanied by 95% confidence intervals (CIs). The extensive search yielded 12,253 citations, from which 22 RCTs fulfilled the eligibility criteria(Ganji-Arjenaki & Rafieian-Kopaei, 2018).

The analysis indicated that probiotics did not confer a discernible advantage over placebo in terms of inducing remission in active ulcerative colitis (RR of failure to attain remission = 0.86; 95% CI = 0.68-1.08). However, within the subset of trials specifically involving VSL#3, a favorable effect seemed to emerge (RR = 0.74; 95% CI = 0.63-0.87). In the context of preventing relapse of quiescent ulcerative colitis, probiotics demonstrated comparability to 5-ASAs (RR = 1.02; 95% CI = 0.85-1.23). Nevertheless, evidence supporting the efficacy of probiotics in inducing remission of active Crohn's disease, preventing relapse of quiescent Crohn's disease, or forestalling relapse of Crohn's disease following surgically induced remission was notably absent.In summary, the results suggest the potential effectiveness of VSL#3 in inducing remission in active ulcerative colitis. Additionally, probiotics may exhibit comparable efficacy to 5-ASAs in preventing relapse of quiescent ulcerative colitis. However, the efficacy of probiotics in the context of Crohn's disease remains uncertain, necessitating further evidence from meticulously conducted randomized controlled trials to ascertain their utility in this context (Derwa et al., 2017; Gosselink et al., 2004)

In a separate study conducted by Mimura et al., the impact of VSL#3—a blend of eight strains encompassing S. thermophilus, Lactobacilus, and Bifidobacterium—on the maintenance of remission in cases of recurrent or refractory pouchitis was evaluated. In this trial, 36 patients with pouchitis, experiencing at least two occurrences within the preceding year or necessitating antibiotics, were randomized into two groups: VSL#3 (n = 20) or placebo (n = 16). The results revealed that remission, serving as secondary prevention for pouchitis, was upheld at the one-year mark in 17 patients (85%) who received VSL#3, whereas only one patient in the placebo group achieved remission ($P < 0.0001$)(Elahi et al., 2008; Guslandi et al., 2000; Mimura et al., 2004)In contrast, the evidence supporting the advantages of probiotics in individuals with Crohn's disease remains notably weaker. In fact, a recent review encompassing five studies in adults and a solitary study in children arrives at the conclusion that the current data fail to substantiate the use of probiotics in both adult and pediatric patients afflicted with Crohn's disease(Guandalini, 2010). This contrast highlights the differential impact and limited efficacy of probiotics across distinct gastrointestinal conditions.

Efficacy for IBS

The primary aim was to clarify the potential efficacy of probiotics in alleviating irritable bowel syndrome (IBS) symptoms amid conflicting randomized controlled trial (RCT) outcomes. A meticulous systematic review employed comprehensive electronic searches in databases like MEDLINE, EMBASE, and Cochrane Controlled Trials Register, spanning 1966 to May 2008. Examination of Digestive Diseases Week (DDW) and United European Gastroenterology Week (UEGW) abstracts, along with author interactions, provided supplementary data. Inclusion criteria mandated parallel group RCTs with $\geq$ 1 week treatment, comparing probiotics to placebo/no treatment in IBS-diagnosed adults. Trials were required to demonstrate improvements in abdominal pain or overall IBS symptoms. Independent researchers meticulously executed selection and data extraction, synthesized through relative risk (RR) for dichotomous data and standardized mean difference (SMD) for continuous data, using random effects models.

From 19 RCTs involving 1650 IBS patients, commendable trial quality emerged with robust randomization and allocation concealment strategies. Among 19 trials, 10 (918 patients) showcased significant probiotic superiority over placebo (RR of IBS not improving = 0.71; 95% CI 0.57-0.88); NNT = 4 (95% CI 3-12.5). Yet, substantial heterogeneity and funnel plot asymmetry warranted scrutiny. In 15 trials (1351 patients), IBS score improvements were observed (SMD = -0.34; 95% CI -0.60 to -0.07), largely due to an outlier trial. In essence, results suggest probiotics might manage IBS symptoms, but their full benefits and effective species/strains remain uncertain, necessitating further investigation(Moayyedi et al., 2010). In an analogous study by(Didari et

al., 2015), potential probiotic benefits in IBS were probed via systematic review and meta-analysis. Searches (Sep 2007 to Dec 2013) led to 24 trials, 15 for meta-analysis and nine for systematic review. These placebo-controlled RCTs evaluated probiotics' efficacy in IBS symptom enhancement, using Jadad scores to assess methodological quality. With 1793 participants, favorable probiotic impact emerged on abdominal pain and global symptom scores, implying potential pain and symptom severity reduction compared to placebo.

In conclusion, while the studies differ in their specific methodology and scope, they share a common goal of investigating the efficacy of probiotics in alleviating symptoms of IBS. Despite the variation in the number of trials examined and the specific outcomes measured, both studies converge in their observations that probiotics hold promise in improving IBS symptoms and warrant further investigation to determine the extent of their benefits and the most effective species and strains.

The intricate challenge of treating irritable bowel syndrome (IBS) persists due to its elusive etiology. Prior clinical trials investigating the efficacy of probiotic Bifidobacterium infantis 35624 (B. infantis) in IBS patients have yielded inconsistent outcomes. This study aimed to comprehensively evaluate the collective impact of B. infantis on mitigating IBS symptom severity, drawing from published data. Employing fixed-effect models, a meta-analysis was conducted to gauge the combined effect of B. infantis on primary outcomes encompassing abdominal pain, bloating/distention, and bowel habit satisfaction. A meticulous systematic review was executed, scouring PubMed, Cochrane Library, and EMBASE databases for randomized controlled trials pitting probiotic B. infantis against placebos in IBS symptom management, up to 31 December 2016. The standardized mean difference (SMD) method facilitated data synthesis due to differing efficacy measurement scales across studies(Yuan et al., 2017).
From the gathered information, five suitable studies emerged, consisting of three with sole probiotic B. infantis usage and two involving composite probiotics containing B. infantis. Intriguingly, the treatment solely with probiotic B. infantis did not yield discernible impacts on IBS patients' abdominal pain, bloating/distention, or bowel habit satisfaction. However, a notable shift occurred among patients who received composite probiotics containing B. infantis, with a significant reduction in abdominal pain (SMD, 0.22; 95% CI, 0.03–0.41) and bloating/distention (SMD, 0.30; 95% CI, 0.04–0.56). Collating data from six studies emphasized a sustained and meaningful reduction in bloating/distention among IBS patients (SMD, 0.21; 95% CI, 0.07–0.35).
Consequently, the findings suggest that composite probiotics containing B. infantis could emerge as a promising therapeutic avenue for alleviating IBS symptoms, notably without significant adverse effects. However, the efficacy of sole probiotic B. infantis in addressing IBS symptoms remains inconclusive, warranting further validation through robust, large-scale randomized clinical trials(Yuan et al., 2017).

While specific strains or combinations might exhibit effectiveness for a particular indication, caution prevails in extrapolating recommendations for specific probiotic or symbiotic products without comprehensive clinical testing in their final form and marketed dosage. Clinical efficacy hinges on various factors, including microbial species, formulation, viability, residence time in the gut, and dosing method. The absence of such testing impedes informed decision-making by healthcare providers and consumers of probiotic products(Ringel et al., 2012)

Future perspective

The field of inflammatory bowel disease (IBD) treatment benefits from preclinical studies highlighting the effectiveness of genetically modified probiotics (gm probiotics) in animal models.The approach involved comprehensive searches across databases like PubMed, Cochrane Library, and others until September 18, 2022, identifying preclinical and clinical studies on gm probiotics in IBD models or patients. In the study Forty-five preclinical studies inducing colitis with sodium dextran sulfate and trinitrobenzene sulfonic acid used eleven genetically modified probiotic species to produce therapeutic agents like IL-10, antimicrobial peptides, antioxidant enzymes, and short-chain fatty acids, showing potential against colitis. Outcomes showed positive impacts of gm probiotics, reducing disease activity and intestinal damage in IBD models.Mechanisms included gut microbiota modulation, beneficial bacteria metabolites, anti-inflammatory cytokine balance, oxidative stress reduction, and improved intestinal barrier.
Regarding gm probiotics secreting IL-10, twelve preclinical studies were analyzed. These studies demonstrated varying impacts on disease activity, colon length, and body weight, with some showing notable improvements compared to wild-type or untreated groups. However, the consistency of results regarding changes in relative body weight remained inconclusive. Conversely, there was a consistent trend indicating the potential of gm probiotics secreting IL-10 to alleviate intestinal damage. A clinical study in Crohn's disease patients hinted at

the feasibility of using gm probioticsL. lactis for mucosal IL-10 delivery, despite limitations due to sample size and outcome measures(Foligné et al., 2006; Gardlik et al., 2012; Qiu et al., 2013; Steidler et al., 2000).

Exploration into the effects of IL-27 and IL-35 in preclinical environments has yielded promising outcomes. Gm probiotics designed to secrete IL-27(Sasaoka et al., 2011)exhibited a robust shield against colitis, evident through reduced intestinal damage and heightened IL-10 expression. Similarly, the proficiency of gm probiotics producing IL-35(Wang et al., 2019)emerged as noteworthy, as they displayed considerable potential in ameliorating intestinal damage, elevating disease activity index scores, and orchestrating cytokine modulations in comparison to their wild-type counterparts. In the sphere of growth factors, which are pivotal for intestinal growth and repair, the inquiries harnessed gm probiotics that engendered KGF-2 or TGF-β(S. Liu et al., 2016). Furthermore, the utilization of gm probiotics for TFF3 delivery showcased augmented protection against acute colitis, although without manifesting a remarkable superiority over the effects of parental strains(Poulsen et al., 1999). The application of gm probiotics to deliver antibodies or receptor antagonists targeting cytokines such as TNFα and IL-1Ra surpassed the efficacy of their wild-type counterparts.In summation, the landscape of preclinical investigations concerning the efficacy of gm probiotics within IBD models holds substantial promise(Chiabai et al., 2019).

The potential benefits encompass a reduction in disease activity and the mitigation of intestinal damage. This bolsters the concept of gm probiotics, particularly those engineered to produce immunoregulatory cytokines, as a viable therapeutic avenue for IBD. Nonetheless, the road toward clinical translation necessitates thorough research and clinical trials to validate these findings, establish safety parameters, and assess effectiveness in human subjects (Zhang et al., 2023). The review's conclusions underscore that gm probiotics indeed hold a certain efficacy in colitis models, attributed to a spectrum of mechanisms. The overarching scarcity of clinical trials, however, accentuates the necessity for intensified focus on gm probiotics exhibiting superior effectiveness and safety in comparison to wild-type counterparts, thus expediting their clinical translation. Moreover, these findings underscore the multifaceted nature of gm probiotic efficacy, shaped by factors such as the choice of wild-type probiotic species or strains, distinct gm probiotic combinations, therapeutic agents, dosing, and the specific IBD model employed(Zhang et al., 2023).

In 2018, a comprehensive meta-analysis assessed thirty-seven studies involving 21 probiotic combinations and 4430 subjects to evaluate probiotics' efficacy in irritable bowel syndrome (IBS). Notably, the probiotic combination LacClean Gold, comprising Bifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus rhamnosus, and Streptococcus thermophiles, showed significance. Likewise, a seven-strain mix of three Bifidobacterium, three Lactobacillus, and one Streptococcus displayed marked IBS symptom improvement. A trend towards enhancing global symptom scores or abdominal pain was observed with LSL#3, a blend of 4 Lactobacilli (L. casei, L. acidophilus, L. delbrueckii subsp. Bulgaricus), 3 Bifidobacteria (B. longum, B. breve, B. infantis), and a Streptococcus (Streptococcussalivarius subsp. thermophilus). However, limitations surfaced regarding specific probiotic combinations, species, strains, and potential IBS subtypes that may benefit. This study underscores probiotics' evolving importance as a potential IBS therapy, with a promising future role (Ford et al., 2018)
The viability of probiotics may be compromised by the harsh conditions of the stomach and the presence of bile salts. Thermal or oxidative stress during preparation and storage can also reduce their effectiveness. To overcome these challenges, developing robust and stable probiotic formulations is crucial. Such formulations are essential to overcome various barriers, including physicochemical, biopharmaceutical, and biological factors, enhancing therapeutic efficacy and clinical utility. This comprehensive review offers an overview of probiotics' pharmaceutical applications, focusing on recent formulation strategies to optimize their delivery. This encompasses diverse dosage forms and innovative technologies to refine probiotic administration. Probiotics-based drug delivery systems have gained attention due to added benefits like inhibiting pathogenic organism adhesion, antimicrobial properties, and immune response modulation.

Oral probiotic delivery encompasses a range of dosage forms such as tablets, capsules, oral films, and hydro gels. To enhance probiotic survival in the gastrointestinal tract, microencapsulation and surface coating techniques are often employed(Teruel et al., 2020). Orally dissolving or disintegrating films (ODFs) have recently gained popularity as patient-centric formulations. Placed on the tongue, ODFs quickly hydrate in saliva, facilitating the rapid release of active substances. These formulations include active ingredients, film-forming polymers, plasticizers, and functional excipients like sweeteners, flavors, and colors tailored to specific needs(Hoffmann et al., 2011).

Nasal probiotic delivery holds promise for airway disease management by influencing epithelial barrier function and the immune system(Martens et al., 2018). This non-invasive, self-administrable approach offers rapid onset of action. A nasal formulation of L. casei AMBR2 through spray drying exhibited viability and morphology retention(Jokicevic et al., 2021). Skin application of viable probiotics can stimulate lactic acid production, reducing pathogenic bacterial growth and enhancing skin immunity(Ammar et al., 2020). Various nanomaterials of distinct sizes, shapes, and compositions have been explored for efficient probiotic encapsulation. Nanostructured material-based formulations show potential in enhancing probiotic resilience. Combining hydrogels and nanomaterials creates nanocomposite systems with small size, stable complexes, high drug loading, reduced toxicity, and improved mechanical strength. Innovative formulations and strategies are reshaping the probiotic delivery landscape, surmounting challenges, and amplifying therapeutic potential(Baral et al., 2021)

Key Safety Considerations While Utilization of Probiotics

Understanding the nuanced aspects of probiotic supplementation is crucial to ensure both safety and effectiveness. The strain-specific nature of probiotics emphasizes that different strains within the same bacterial species can wield distinct impacts on the body. Therefore, prior to usage, a meticulous assessment of the safety profile of a specific strain becomes indispensable, as highlighted by (Hill et al., 2014).

Integral to this evaluation is the consideration of interactions between probiotics and the host's immune system, which holds the potential to influence both safety and potential benefits. This nexus between probiotics and the immune response is expounded upon by(Schiffrin et al., 2007). Particularly, for individuals with compromised immune systems, such as those with conditions like HIV/AIDS, organ transplants, or undergoing chemotherapy, the cautious employment of probiotics is advised. This is due to the elevated risk of adverse effects, where probiotics could inadvertently lead to infections or complications in these populations, as articulated by(Doron & Snydman, 2015). Furthermore, the confluence of pre-existing medical conditions with probiotic usage warrants scrupulous consideration. Instances such as severe pancreatitis or short bowel syndrome exemplify conditions that could potentially be exacerbated by probiotics. The importance of judiciously assessing an individual's medical history and existing conditions before endorsing probiotics is underscored by research conducted by (Hempel et al., 2012; Mack et al., 1999). In the pursuit of well-informed recommendations, these factors collectively advocate for a comprehensive understanding of the intricate interplay between strain specificity, host immune response, immunocompromised states, and pre-existing medical conditions in the realm of probiotic utilization.

Probiotic supplementation, while generally considered safe, is not without its potential risks, which are important to recognize and address. A notable concern is the rare association of certain probiotic strains with infections, particularly in individuals with underlying health conditions. This risk is exacerbated in critically ill patients or those with medical devices, as highlighted by(Sanders et al., 2010). Furthermore, the initial use of probiotics can occasionally trigger symptoms like gas, bloating, and gastrointestinal discomfort. These symptoms are typically temporary and tend to diminish as the body acclimatizes to the probiotics. Though uncommon, allergic reactions to components of probiotic supplements can occur, necessitating caution among individuals with allergies or sensitivities to specific ingredients within probiotic formulations, as emphasized by (Mack et al., 1999). It's worth noting that an excessive immune response to certain probiotics can lead to immune system overstimulation and subsequent inflammation in susceptible individuals, as indicated by (McFarland, 2010). In scenarios involving critically ill patients, the potential adverse effects of probiotics, including infections and other complications, are heightened, as documented by(Barraud et al., 2010). Similarly, among surgical patients, especially those undergoing abdominal surgeries, the use of probiotics may entail risks of complications, as underlined by (Rayes et al., 2005). These insights collectively underscore the need for a nuanced approach to probiotic supplementation, with a keen awareness of the potential risks and careful consideration of individual health circumstances.

Navigating the realm of probiotic usage demands an appreciation for the intricate interplay of various factors that influence safety and efficacy. Individual responses to probiotics can be notably diverse, resulting in unpredictable adverse effects or even negligible benefits, a phenomenon expounded by(Ouwehand, 2017). The safety landscape further varies across distinct patient populations, encompassing adults, children, the elderly, and immunocompromised individuals, as delineated by(Boyle & Tang, 2006). Particularly in pediatric and elderly populations, whose immune and gastrointestinal systems may be more delicate, prudence dictates the

meticulous selection and vigilant monitoring of probiotic administration, an assertion elucidated by (D'souza et al., 2002). The dimensions of dosage and administration intricacies are pivotal in shaping the safety and effectiveness of probiotics, an insight underscored by(McFarland, 2010). Moreover, the duration of probiotic usage assumes significance, with potential variations in outcomes between long-term and short-term consumption, a perspective presented by(O'Mahony et al., 2005). The confluence of probiotics with other interventions, including antibiotics or dietary supplements, necessitates careful consideration due to their potential impact on safety and effectiveness, as posited by (Ouwehand, 2017). The potential influence of probiotics on medication absorption, particularly in interacting with medications, merits recognition as it could affect absorption within the gut, as highlighted by (McFarland, 2010). In the realm of antibiotic interactions, caution is warranted, given that probiotics might interact with antibiotics, potentially affecting the antibiotics' efficacy. To mitigate this potential interaction, the recommendation to separate the administration of probiotics and antibiotics by several hours is prudent, as proposed by (Boyle & Tang, 2006). In embracing these multifaceted nuances, one can foster a more comprehensive understanding of the intricacies that underpin probiotic safety and effectiveness in diverse scenarios.

In the realm of probiotic utilization, a range of considerations shape the landscape of safety and effectiveness. Common gastrointestinal symptoms, like bloating, gas, abdominal discomfort, and diarrhea, often manifest during the initial stages of probiotic intake, as noted by (McFarland, 2010). Beyond these immediate effects, concerns extend to potential antibiotic resistance gene transfer, wherein worries loom regarding the horizontal transfer of antibiotic resistance genes from probiotic strains to pathogenic bacteria within the gut, as explored by(Imperial & Ibana, 2016). A pertinent facet is the varied regulatory oversight that envelops probiotics, with their classification ranging from dietary supplements to medical products across regions. This regulatory intricacy, as elucidated by the (*Probiotics in Food*, n.d.)necessitates comprehension for safeguarding consumer safety.

In this landscape, the assurance of product quality and purity takes center stage. The potential risks posed by contaminated or inadequately manufactured probiotic products underscore the significance of seeking items subjected to rigorous purity and potency testing, a standpoint endorsed by (Sanders et al., 2010). Moreover, the underpinning research methodology and study design play a pivotal role in shaping the reliability of safety data. The quality of clinical investigations and the research methodologies employed to gauge probiotic safety stand as paramount determinants, as highlighted by (Hempel et al., 2012)To fully comprehend the intricacies of probiotic safety, one must embrace these multifaceted dimensions, encompassing gastrointestinal symptoms, antibiotic resistance transfer, regulatory intricacies, product quality, and the rigorous methodologies underpinning research.

Conclusion

Inconclusion, this comprehensive review thoroughly explores the multifaceted contributions of probiotics to mitigating gastrointestinal disorders, with a keen emphasis on their effectiveness, safety considerations, and promising avenues for advancement. The inquiry delves deep into the intricate complexities presented by functional gastrointestinal disorders (FGIDs), shedding light on the profound implications these challenges have on patients' overall well-being(Drossman et al., 1993). The pivotal role of probiotics in modulating the gut microbiota comes to the fore, revealing their potential to address a spectrum of conditions including infectious and antibiotic-associated diarrhea, as well as irritable bowel syndrome (IBS), bolstered by the robust evidence from clinical investigations and meta-analyses(Parker et al., 2018)(Chang et al., 2006; Corney & Stanton, 1990; Sandler, 1990; Simren et al., 2001; Strid et al., 2001; Talley et al., 1991, 1992, 1995, 1998, 2001; TEMPLE et al., n.d.). The paramount importance of safety, particularly in light of strain-specific interactions and the vulnerability of immunocompromised individuals, is meticulously underscored. Moreover, the review casts a discerning eye toward future research trajectories, envisioning innovative pharmaceutical formulations and the untapped potential of genetically modified probiotics to elevate their therapeutic utility(Hill et al., 2014). In synopsis, this exhaustive analysis serves as a beacon of enlightenment for clinicians, researchers, and individuals, illuminating the multifaceted impact of probiotics. It ensures the integration of judicious and effective strategies for managing gastrointestinal health, while charting an auspicious course towards future advancements in the realm of healthcare.

References

1. Agamennone, V., Krul, C. A. M., Rijkers, G., & Kort, R. (2018). A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in The Netherlands. *BMC Gastroenterology*, *18*(1), 1–12.
2. Albillos, A., De Gottardi, A., & Rescigno, M. (2020a). The gut-liver axis in liver disease: Pathophysiological basis for therapy. *Journal of Hepatology*, *72*(3), 558–577.
3. Albillos, A., De Gottardi, A., & Rescigno, M. (2020b). The gut-liver axis in liver disease: Pathophysiological basis for therapy. *Journal of Hepatology*, *72*(3), 558–577.
4. Allen, S. J., Martinez, E. G., Gregorio, G. V, & Dans, L. F. (2010). Probiotics for treating acute infectious diarrhoea. *Cochrane Database of Systematic Reviews*, *11*.
5. Alvarez-Olmos, M. I., & Oberhelman, R. A. (2001). Probiotic agents and infectious diseases: a modern perspective on a traditional therapy. *Clinical Infectious Diseases*, *32*(11), 1567–1576.
6. Ammar, H. O., Mohamed, M. I., Tadros, M. I., &Fouly, A. A. (2020). High frequency ultrasound mediated transdermal delivery of ondansetron hydrochloride employing bilosomal gel systems: ex-vivo and in-vivo characterization studies. *Journal of Pharmaceutical Investigation*, *50*, 613–624.
7. World Gastroenterology Organisation. Probiotics and prebiotics. 2017.
8. Baral, K. C., Bajracharya, R., Lee, S. H., & Han, H.-K. (2021). Advancements in the pharmaceutical applications of probiotics: Dosage forms and formulation technology. *International Journal of Nanomedicine*, 7535–7556.
9. Barraud, D., Blard, C., Hein, F., Marçon, O., Cravoisy, A., Nace, L., Alla, F., Bollaert, P.-E., & Gibot, S. (2010). Probiotics in the critically ill patient: a double blind, randomized, placebo-controlled trial. *Intensive Care Medicine*, *36*(9), 1540–1547. https://doi.org/10.1007/s00134-010-1927-0
10. Boyle, R. J., & Tang, M. L. K. (2006). The Role of Probiotics in the Management of Allergic Disease. *Clinical & Experimental Allergy*, *36*(5), 568–576. https://doi.org/https://doi.org/10.1111/j.1365-2222.2006.02472.x
11. Brown, K., DeCoffe, D., Molcan, E., & Gibson, D. L. (2012). Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. *Nutrients*, *4*(8), 1095–1119.
12. Bungau, S. G., Behl, T., Singh, A., Sehgal, A., Singh, S., Chigurupati, S., Vijayabalan, S., Das, S., & Palanimuthu, V. R. (2021). Targeting probiotics in rheumatoid arthritis. *Nutrients*, *13*(10), 3376.
13. Chang, L., Toner, B. B., Fukudo, S., Guthrie, E., Locke, G. R., Norton, N. J., & Sperber, A. D. (2006). Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. *Gastroenterology*, *130*(5), 1435–1446.
14. Chiabai, M. J., Almeida, J. F., de Azevedo, M. G. D., Fernandes, S. S., Pereira, V. B., de Castro, R. J. A., Jerônimo, M. S., Sousa, I. G., de Souza Vianna, L. M., & Miyoshi, A. (2019). Mucosal delivery of Lactococcus lactis carrying an anti-TNF scFv expression vector ameliorates experimental colitis in mice. *BMC Biotechnology*, *19*, 1–12.
15. Corney, R. H., & Stanton, R. (1990). Physical symptom severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome. *Journal of Psychosomatic Research*, *34*(5), 483–491.
16. De Kort, S., Keszthelyi, D., &Masclee, A. A. M. (2011). Leaky gut and diabetes mellitus: what is the link? *Obesity Reviews*, *12*(6), 449–458.
17. De Roock, S., Van Elk, M., Van Dijk, M. E. A., Timmerman, H. M., Rijkers, G. T., Prakken, B. J., Hoekstra, M. O., & De Kleer, I. M. (2010). Lactic acid bacteria differ in their ability to induce functional regulatory T cells in humans. *Clinical & Experimental Allergy*, *40*(1), 103–110.
18. de Vrese, M., Stegelmann, A., Richter, B., Fenselau, S., Laue, C., &Schrezenmeir, J. (2001). Probiotics—compensation for lactase insufficiency. *The American Journal of Clinical Nutrition*, *73*(2), 421s–429s.
19. Derwa, Y., Gracie, D. J., Hamlin, P. J., & Ford, A. C. (2017). Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. *Alimentary Pharmacology & Therapeutics*, *46*(4), 389–400. https://doi.org/https://doi.org/10.1111/apt.14203
20. Didari, T., Mozaffari, S., Nikfar, S., & Abdollahi, M. (2015). Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. *World Journal of Gastroenterology: WJG*, *21*(10), 3072.
21. Doron, S., & Snydman, D. (2015). Risk and Safety of Probiotics. *Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America*, *60 Suppl 2*, S129-34. https://doi.org/10.1093/cid/civ085

22. Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002). AGA technical review on irritable bowel syndrome. *Gastroenterology*, *123*(6), 2108–2131.
23. Drossman, D. A., Li, Z., Andruzzi, E., Temple, R. D., Talley, N. J., Grant Thompson, W., Whitehead, W. E., Janssens, J., Funch-Jensen, P., &Corazziari, E. (1993). US householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact. *Digestive Diseases and Sciences*, *38*, 1569–1580.
24. D'souza, A. L., Rajkumar, C., Cooke, J., & Bulpitt, C. J. (2002). Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. *Bmj*, *324*(7350), 1361.
25. EJ, V. (1994). Colonization resistance. *Antimicrob Agents Chemother*, *38*, 409–414.
26. Elahi, B., Nikfar, S., Derakhshani, S., Vafaie, M., & Abdollahi, M. (2008). On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. *Digestive Diseases and Sciences*, *53*, 1278–1284.
27. Ewaschuk, J. B., & Dieleman, L. A. (2006). Probiotics and prebiotics in chronic inflammatory bowel diseases. *World Journal of Gastroenterology: WJG*, *12*(37), 5941.
28. FAO/WHO. (2001). *Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Expert Consultation Report*.
29. Fasano, A., & Shea-Donohue, T. (2005). Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. *Nature Clinical Practice Gastroenterology & Hepatology*, *2*(9), 416–422.
30. Foligné, B., Nutten, S., Steidler, L., Dennin, V., Goudercourt, D., Mercenier, A., & Pot, B. (2006). Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: technical and microbiological aspects. *Digestive Diseases and Sciences*, *51*, 390–400.
31. Ford, A. C., Harris, L. A., Lacy, B. E., Quigley, E. M. M., & Moayyedi, P. (2018). Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. *Alimentary Pharmacology & Therapeutics*, *48*(10), 1044–1060.
32. Ford, A. C., Thabane, M., Collins, S. M., Moayyedi, P., Garg, A. X., Clark, W. F., & Marshall, J. K. (2010). Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. *Gastroenterology*, *138*(5), 1727–1736.
33. Fuss, I. J., Heller, F., Boirivant, M., Leon, F., Yoshida, M., Fichtner-Feigl, S., Yang, Z., Exley, M., Kitani, A., & Blumberg, R. S. (2004). Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. *The Journal of Clinical Investigation*, *113*(10), 1490–1497.
34. Ganji-Arjenaki, M., & Rafieian-Kopaei, M. (2018). Probiotics are a good choice in remission of inflammatory bowel diseases: A meta analysis and systematic review. *Journal of Cellular Physiology*, *233*(3), 2091–2103. https://doi.org/https://doi.org/10.1002/jcp.25911
35. Gardlik, R., Palffy, R., &Celec, P. (2012). Recombinant probiotic therapy in experimental colitis in mice. *Folia Biologica*, *58*(6), 238.
36. Gosselink, M. P., Schouten, W. R., van Lieshout, L. M. C., Hop, W. C. J., Laman, J. D., &Ruseler-vanEmbden, J. G. H. (2004). Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. *Diseases of the Colon & Rectum*, *47*, 1519–1525.
37. Guandalini, S. (2010). Update on the role of probiotics in the therapy of pediatric inflammatory bowel disease. *Expert Review of Clinical Immunology*, *6*(1), 47–54.
38. Guarner, F., Khan, A. G., Garisch, J., Eliakim, R., Gangl, A., Thomson, A., Krabshuis, J., Le Mair, T., Kaufmann, P., & De Paula, J. A. (2008). World Gastroenterology Organisation Practice Guideline: Probiotics and Prebiotics-May 2008: guideline. *South African Gastroenterology Review*, *6*(2), 14–25.
39. Guarner, F., &Malagelada, J.-R. (2003). Gut flora in health and disease. *The Lancet*, *361*(9356), 512–519.
40. Guslandi, M., Mezzi, G., Sorghi, M., &Testoni, P. A. (2000). Saccharomyces boulardii in maintenance treatment of Crohn's disease. *Digestive Diseases and Sciences*, *45*, 1462–1464.
41. Hahn, B. A., Yan, S., &Strassels, S. (1999). Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. *Digestion*, *60*(1), 77–81.

42. Halpern, G. M., Prindiville, T., Blankenburg, M., Hsia, T., & Gershwin, M. E. (1996). Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. *American Journal of Gastroenterology (Springer Nature)*, *91*(8).
43. Harris, L. A., &Baffy, N. (2017). Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome. *Postgraduate Medicine*, *129*(8), 872–888.
44. Hempel, S., Newberry, S., Maher, A., Wang, Z., Miles, J., Shanman, R., Johnsen, B., &Shekelle, P. (2012). Probiotics for the Prevention and Treatment of Antibiotic-Associated Diarrhea A Systematic Review and Meta-analysis. *JAMA : The Journal of the American Medical Association*, *307*, 1959–1969. https://doi.org/10.1001/jama.2012.3507
45. Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., Morelli, L., Canani, R. B., Flint, H. J., & Salminen, S. (2014). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nature Reviews Gastroenterology & Hepatology*.
46. Hilton, E., Kolakowski, P., Singer, C., & Smith, M. (1997). Efficacy of Lactobacillus GG as a diarrheal preventive in travelers. *Journal of Travel Medicine*, *4*(1), 41–43.
47. Hoffmann, E. M., Breitenbach, A., & Breitkreutz, J. (2011). Advances in orodispersible films for drug delivery. *Expert Opinion on Drug Delivery*, *8*(3), 299–316.
48. Hoveyda, N., Heneghan, C., Mahtani, K. R., Perera, R., Roberts, N., &Glasziou, P. (2009). A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. *BMC Gastroenterology*, *9*(1), 15. https://doi.org/10.1186/1471-230X-9-15
49. Imperial, I. C. V. J., & Ibana, J. A. (2016). Addressing the Antibiotic Resistance Problem with Probiotics: Reducing the Risk of Its Double-Edged Sword Effect. *Frontiers in Microbiology*, *7*. https://www.frontiersin.org/articles/10.3389/fmicb.2016.01983
50. Jokicevic, K., Kiekens, S., Byl, E., De Boeck, I., Cauwenberghs, E., Lebeer, S., &Kiekens, F. (2021). Probiotic nasal spray development by spray drying. *European Journal of Pharmaceutics and Biopharmaceutics*, *159*, 211–220.
51. Kailasapathy, K., & Chin, J. (2000). Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp. *Immunology and Cell Biology*, *78*(1), 80–88.
52. König, J., Wells, J., Cani, P. D., García-Ródenas, C. L., MacDonald, T., Mercenier, A., Whyte, J., Troost, F., & Brummer, R.-J. (2016). Human intestinal barrier function in health and disease. *Clinical and Translational Gastroenterology*, *7*(10), e196.
53. Liu, S., Li, Y., Deng, B., & Xu, Z. (2016). Recombinant Lactococcus lactis expressing porcine insulin-like growth factor I ameliorates DSS-induced colitis in mice. *BMC Biotechnology*, *16*(1), 1–8.
54. Liu, Y., Wang, J., & Wu, C. (2022). Modulation of gut microbiota and immune system by probiotics, pre-biotics, and post-biotics. *Frontiers in Nutrition*, *8*, 634897.
55. Mack, D., Michail, S., Wei, S., McDougall, L., & Hollingsworth, M. (1999). Probiotics inhibit enteropathogenic E. Coli adherence in vitro by inducing intestinal mucin gene expression. *The American Journal of Physiology*, *276*, G941-50. https://doi.org/10.1152/ajpgi.1999.276.4.G941
56. Madlala, T., Okpeku, M., & Adeleke, M. A. (2021). Understanding the interactions between Eimeria infection and gut microbiota, towards the control of chicken coccidiosis: a review. *Parasite*, *28*.
57. Martens, K., Pugin, B., De Boeck, I., Spacova, I., Steelant, B., Seys, S. F., Lebeer, S., & Hellings, P. W. (2018). Probiotics for the airways: potential to improve epithelial and immune homeostasis. *Allergy*, *73*(10), 1954–1963.
58. McFarland, L. V. (2010). Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. *World Journal of Gastroenterology: WJG*, *16*(18), 2202.
59. Mimura, T., Rizzello, F., Helwig, U., Poggioli, G., Schreiber, S., Talbot, I. C., Nicholls, R. J., Gionchetti, P., Campieri, M., & Kamm, M. A. (2004). Once daily high dose probiotic therapy (VSL# 3) for maintaining remission in recurrent or refractory pouchitis. *Gut*, *53*(1), 108–114.
60. Moayyedi, P., Ford, A. C., Talley, N. J., Cremonini, F., Foxx-Orenstein, A. E., Brandt, L. J., & Quigley, E. M. M. (2010). The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. *Gut*, *59*(3), 325. https://doi.org/10.1136/gut.2008.167270
61. Nagao-Kitamoto, H., Kitamoto, S., Kuffa, P., & Kamada, N. (2016). Pathogenic role of the gut microbiota in gastrointestinal diseases. *Intestinal Research*, *14*(2), 127–138.
62. O'Hara, A. M., & Shanahan, F. (2006). The gut flora as a forgotten organ. *EMBO Reports*, *7*(7), 688–693.

63. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G. C., Kiely, B., Collins, J. K., & Shanahan, F. (2005). Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. *Gastroenterology*, *128*(3), 541–551.
64. Ouwehand, A. C. (2017). A review of dose-responses of probiotics in human studies. *Beneficial Microbes*, *8*(2), 143–151. https://doi.org/10.3920/BM2016.0140
65. Parker, E. A., Roy, T., D'Adamo, C. R., & Wieland, L. S. (2018). Probiotics and gastrointestinal conditions: An overview of evidence from the Cochrane Collaboration. *Nutrition*, *45*, 125–134.
66. Peng, M., Tabashsum, Z., Anderson, M., Truong, A., Houser, A. K., Padilla, J., Akmel, A., Bhatti, J., Rahaman, S. O., & Biswas, D. (2020). Effectiveness of probiotics, prebiotics, and prebiotic-like components in common functional foods. *Comprehensive Reviews in Food Science and Food Safety*, *19*(4), 1908–1933.
67. Poulsen, S. S., Thulesen, J., Christensen, L., Nexø, E., & Thim, L. (1999). Metabolism of oral trefoil factor 2 (TFF2) and the effect of oral and parenteral TFF2 on gastric and duodenal ulcer healing in the rat. *Gut*, *45*(4), 516–522.
68. *Probiotics in food*. (n.d.). Retrieved August 15, 2023, from https://www.fao.org/3/a0512e/a0512e.pdf
69. Putignani, L., Del Chierico, F., Vernocchi, P., Cicala, M., Cucchiara, S., Dallapiccola, B., & Group, D. S. (2016). Gut microbiota dysbiosis as risk and premorbid factors of IBD and IBS along the childhood–adulthood transition. *Inflammatory Bowel Diseases*, *22*(2), 487–504.
70. Qiu, Z. B., Chen, J., Chen, J. J., Rong, L., Ding, W. Q., Yang, H. J., & Zhong, L. (2013). Effect of recombinant L actobacilluscasei expressing interleukin-10 in dextran sulfate sodium-induced colitis mice. *Journal of Digestive Diseases*, *14*(2), 76–83.
71. Rayes, N., Seehofer, D., Theruvath, T., Schiller, R., Langrehr, J., Jonas, S., Bengmark, S., & Neuhaus, P. (2005). Supply of Pre- and Probiotics Reduces Bacterial Infection Rates After Liver Transplantation-A Randomized, Double-Blind Trial. *American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons*, *5*, 125–130. https://doi.org/10.1111/j.1600-6143.2004.00649.x
72. Reid, G., Sanders, M. E., Gaskins, H. R., Gibson, G. R., Mercenier, A., Rastall, R., Roberfroid, M., Rowland, I., Cherbut, C., &Klaenhammer, T. R. (2003). New scientific paradigms for probiotics and prebiotics. *Journal of Clinical Gastroenterology*, *37*(2), 105–118.
73. Ringel, Y., Quigley, E. M. M., & Lin, H. C. (2012). Using probiotics in gastrointestinal disorders. *The American Journal of Gastroenterology Supplements*, *1*(1), 34.
74. Rodiño-Janeiro, B. K., Vicario, M., Alonso-Cotoner, C., Pascua-García, R., & Santos, J. (2018). A review of microbiota and irritable bowel syndrome: future in therapies. *Advances in Therapy*, *35*, 289–310.
75. Sanders, M., Akkermans, L., Haller, D., Hammerman, C., Heimbach, J., Hörmannsperger, G., Huys, G., Levy, D., Lutgendorff, F., Mack, D., Phothirath, P., Solano-Aguilar, G., & Vaughan, E. (2010). Safety assessment of probiotics for human use. *Gut Microbes*, *1*, 164–185. https://doi.org/10.4161/gmic.1.3.12127
76. Sanderson, I. R., & Walker, W. A. (1993). Uptake and transport of macromolecules by the intestine: possible role in clinical disorders (an update). *Gastroenterology*, *104*(2), 622–639.
77. Sandler, R. S. (1990). Epidemiology of irritable bowel syndrome in the United States. *Gastroenterology*, *99*(2), 409–415.
78. Sanz, Y., & De Palma, G. (2009). Gut microbiota and probiotics in modulation of epithelium and gut-associated lymphoid tissue function. *International Reviews of Immunology*, *28*(6), 397–413.
79. Sasaoka, T., Ito, M., Yamashita, J., Nakajima, K., Tanaka, I., Narita, M., Hara, Y., Hada, K., Takahashi, M., & Ohno, Y. (2011). Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells. *American Journal of Physiology-Gastrointestinal and Liver Physiology*, *300*(4), G568–G576.
80. Schiffrin, E., Thomas, D., Kumar, V., Brown, C., Hager, C., Hof, M., Morley, J., &Guigoz, Y. (2007). Schiffrin EJ, Thomas DR, Kumar VB, Brown C, Hager C. Systemic inflammatory markers in older persons: the effect of oral nutritional supplementation with prebiotics. J Nutr Health Aging 11, 475-479. *The Journal of Nutrition, Health & Aging*, *11*, 475–479.
81. Schultz, M., & Sartor, R. B. (2000). Probiotics and inflammatory bowel diseases. *The American Journal of Gastroenterology*, *95*(1), S19–S21.

82. Simren, M., Abrahamsson, H., Svedlund, J., & Björnsson, E. S. (2001). Quality of life in patients with irritable bowel syndrome seen in referral centers versus primary care: the impact of gender and predominant bowel pattern. *Scandinavian Journal of Gastroenterology*, *36*(5), 545–552.
83. Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humarán, L. G., Gratadoux, J.-J., Blugeon, S., Bridonneau, C., Furet, J.-P., &Corthier, G. (2008). Faecalibacteriumprausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proceedings of the National Academy of Sciences*, *105*(43), 16731–16736.
84. Steidler, L., Hans, W., Schotte, L., Neirynck, S., Obermeier, F., Falk, W., Fiers, W., &Remaut, E. (2000). Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. *Science*, *289*(5483), 1352–1355.
85. Strid, H., Norström, M., Sjöberg, J., Simren, M., Svedlund, J., Abrahamsson, H., & Björnsson, E. S. (2001). Impact of sex and psychological factors on the water loading test in functional dyspepsia. *Scandinavian Journal of Gastroenterology*, *36*(7), 725–730.
86. Strober, W., Fuss, I., & Mannon, P. (2007). The fundamental basis of inflammatory bowel disease. *The Journal of Clinical Investigation*, *117*(3), 514–521.
87. Sullivan, Å., & Nord, C. E. (2002a). Probiotics in human infections. *Journal of Antimicrobial Chemotherapy*, *50*(5), 625–627.
88. Sullivan, Å., & Nord, C. E. (2002b). The place of probiotics in human intestinal infections. *International Journal of Antimicrobial Agents*, *20*(5), 313–319.
89. Sullivan, Å., & Nord, C. E. (2005). Probiotics and gastrointestinal diseases. *Journal of Internal Medicine*, *257*(1), 78–92.
90. Talley, N. J., Boyce, P., & Jones, M. (1998). Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. *Gut*, *42*(5), 690–695.
91. Talley, N. J., Verlinden, M., & Jones, M. (2001). Can symptoms discriminate among those with delayed or normal gastric emptying in dysmotility-like dyspepsia? *The American Journal of Gastroenterology*, *96*(5), 1422–1428.
92. Talley, N. J., Zinsmeister, A. R., & Melton III, L. J. (1995). Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. *American Journal of Epidemiology*, *142*(1), 76–83.
93. Talley, N. J., Zinsmeister, A. R., Schleck, C. D., & Melton III, L. J. (1992). Dyspepsia and dyspepsia subgroups: a population-based study. *Gastroenterology*, *102*(4), 1259–1268.
94. Talley, N. J., Zinsmeister, A. R., Van Dyke, C., & Melton III, L. J. (1991). Epidemiology of colonic symptoms and the irritable bowel syndrome. *Gastroenterology*, *101*(4), 927–934.
95. Targan, S. R. (2006). Current limitations of IBD treatment: where do we go from here? *Annals of the New York Academy of Sciences*, *1072*(1), 1–8.
96. TEMPLE, R. D., TALLEY, N. J., THOMPSON, W. G., WHITEHEAD, W. E., JANSSENS, J., FUNCH-JENSEN, P., CORAZZIARI, E., RICHTER, J. E., & KOCH, G. G. (n.d.). *US Householder Survey of Functional*.
97. Teruel, A. H., Gonzalez-Alvarez, I., Bermejo, M., Merino, V., Marcos, M. D., Sancenon, F., Gonzalez-Alvarez, M., &Martinez-Mañez, R. (2020). New insights of oral colonic drug delivery systems for inflammatory bowel disease therapy. *International Journal of Molecular Sciences*, *21*(18), 6502.
98. Thompson-Chagoyán, O. C., Maldonado, J., & Gil, A. (2005). Aetiology of inflammatory bowel disease (IBD): role of intestinal microbiota and gut-associated lymphoid tissue immune response. *Clinical Nutrition*, *24*(3), 339–352.
99. TONG, J. L., RAN, Z. H., SHEN, J., ZHANG, C. X., & XIAO, S. D. (2007). Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. *Alimentary Pharmacology & Therapeutics*, *25*(2), 155–168. https://doi.org/https://doi.org/10.1111/j.1365-2036.2006.03179.x
100. Verna, E. C., &Lucak, S. (2010). Use of probiotics in gastrointestinal disorders: what to recommend? *Therapeutic Advances in Gastroenterology*, *3*(5), 307–319.
101. Walker, M. M., Talley, N. J., Inganäs, L., Engstrand, L., Jones, M. P., Nyhlin, H., Agréus, L., Kjellstrom, L., Öst, Å., & Andreasson, A. (2015). Colonic spirochetosis is associated with colonic eosinophilia and irritable bowel syndrome in a general population in Sweden. *Human Pathology*, *46*(2), 277–283.

102. Wang, J., Tian, M., Li, W., & Hao, F. (2019). Preventative delivery of IL-35 by Lactococcus lactis ameliorates DSS-induced colitis in mice. *Applied Microbiology and Biotechnology*, *103*, 7931–7941.
103. Whorwell, P. J., Altringer, L., Morel, J., Bond, Y., Charbonneau, D., O'mahony, L., Kiely, B., Shanahan, F., & Quigley, E. M. M. (2006). Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. *Official Journal of the American College of Gastroenterology| ACG*, *101*(7), 1581–1590.
104. Yousefi, B., Eslami, M., Ghasemian, A., Kokhaei, P., Salek Farrokhi, A., & Darabi, N. (2019). Probiotics importance and their immunomodulatory properties. *Journal of Cellular Physiology*, *234*(6), 8008–8018.
105. Yuan, F., Ni, H., Asche, C. V, Kim, M., Walayat, S., & Ren, J. (2017). Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. *Current Medical Research and Opinion*, *33*(7), 1191–1197. https://doi.org/10.1080/03007995.2017.1292230
106. Zhang, T., Zhang, J., & Duan, L. (2023). The Role of Genetically Engineered Probiotics for Treatment of Inflammatory Bowel Disease: A Systematic Review. *Nutrients*, *15*(7), 1566.